We evaluated 18 acute myeloblastic leukaemia (AML) and myelodysplastic syndrome (MDS) patients with abnormal karyotype at diagnosis who underwent peripheral blood stem cell (PBSC) transplantation. To evaluate the presence of residual tumour cells, bone marrow (BM) samples and PBSC collections were analysed by cytogenetics and in selected cases also by fluorescence in situ hybridisation (FISH) and molecular studies. All patients were considered to be in morphologic and cytogenetic complete remission (CR) at the time of mobilisation. Seven patients showed neoplastic cells in PBSC harvest and/or BM specimen before reinfusion. Cytogenetic studies revealed contamination in apheretic collections in one patient only, while three patients had BM but not PBSC contamination. Three more patients had leukaemic cells both in the BM and PBSC. All but one (with only BM contamination) of these patients relapsed within 9 months. However, five more patients relapsed after transplantion: in four cases there was no cytogenetic sign of contamination either in PBSC or BM cells and in one case no molecular evidence was revealed either. This study suggests that, whereas the presence of leukaemic cells in autologous grafts correlates with a poor prognosis, the lack of detection of tumour cells is not always predictive of long-term disease-free survival. More importantly, PBSC collections from AML patients are not contaminated by leukaemic cells if the BM is disease-free.
ABMT causes significant morbidity and mortality. Clinical application of circulating stem cells for autologous transplantation is steadily expanding. Several investigators have suggested that in AML patients the reinfusion of peripheral blood stem cells (PBSC) after myeloablative therapy might result in a more rapid engraftment than with bone marrow (BM) stem cells. [3] [4] [5] [6] However, the high relapse rate reported in previous papers 3, 7 suggests that returning a larger quantity of cells to patients than in conventional ABMT may increase the probability of reinfusing leukaemic cells. In this regard, leukaemic relapse remains the most frequent cause of treatment failure in AML patients, and preliminary non-randomised investigations did not report any advantage for PBSC over ABMT 3, 8 in terms of disease-free survival and overall survival rate. The issue of leukaemia-free autografting has recently been underscored by gene-marking studies showing that residual contaminating AML cells contribute to disease recurrence. 9 Thus, one of the major issues in the use of autologous blood stem cell transplantation (ABSCT) is the possibility that the PBSC harvest may be heavily contamined with leukaemic cells.
In the present study, we investigated leukaemic cell contamination in PBSC harvests and in BM specimens before autograft by cytogenetics and/or fluorescence in situ hybridisation (FISH) and/or retrotranscriptase polymerase chain reaction (RT-PCR)-based studies according to the chromosomal abnormalities present at diagnosis in 18 patients with AML or myelodysplastic syndrome (MDS).
Materials and methods

Patients
From May 1994 to February 1997, 38 patients with AML or MDS were submitted to autologous PBSC transplantation at our institution. All these patients were studied cytogenetically at diagnosis and 18 showed an abnormal karyotype ( Table 1) .
The apheresis products and the BM, before and serially after transplantation, were studied in these patients. The clinical data of the 18 patients are shown in Table 2 : 10 were females and eight males, median age was 44.5 years (range 22-60). FAB classification was M0, M3, M5 in one patient, M1 and M2 in two patients, M4 in six patients; s-AML = secondary AML; t-AML = therapy-related AML; NOVIA = cytosine-arabinoside (Ara-C 500 mg/m 2 twice a day, days 1-5) and mitoxantrone (8 mg/m 2 /day, days 4-6); FLAN = fludarabine (30 mg/m 2 , for 5 days), cytosine-arabinoside (2 g/m 2 , for 5 days) and mitoxantrone (6 mg/m 2 , for 3 days). G-CSF (5 g/kg day) was given to all patients from day +1 after chemotherapy until the completion of PBSC collection. The patient was submtited to ABMT. two patients had AML post-MDS and one patient AML secondary to multiple myeloma (MM); two patients had refractory anaemia with excess of blasts in tranformation (RAEB-T). The median time between diagnosis and PBSC harvest was 4 months. All patients were considered to be in morphologic and cytogenetic CR at the time of mobilisation. Thirteen patients were reinfused in first CR, one patient (No. 17) in second CR, two patients (Nos 2 and 11) in early relapse and two patients were not reinfused because of overt relapse (No. 14) or inadequate haematological recovery following consolidation therapy (No. 15).
Mobilisation protocol and PBSC collection
Induction and consolidation therapy, apheresis collection and conditioning regimen were performed according to the procedures already described 10 and shown in Table 2 . Briefly, leukaemic patients in CR were treated with , for 5 days) and mitoxantrone (6 mg/m 2 , for 3 days) (FLAN), followed by the administration of granulocyte colony-stimulating factor (G-CSF, filgrastim) at the dose of 5 g/kg/day subcutaneously. G-CSF treatment was continued until the completion of PBSC collection. Once the CD34 + cell count was more than 10 000/ml, patients underwent leukapheresis using a Baxter (Rome, Italy) CS 3000 plus blood cell separator. 11 As a part of a phase I study, in five cases (Nos 3, 6, 8, 9 and 17) the aphereses were treated with the combination of the alkylating agent nitrogen mustard (NM; concentrations ranging from 0.25 to 1.25 g/ml) and etoposide (VP-16; constant dose of 20 g/ml). Two patients (Nos 3 and 9) were resistant to the induction therapy; two patients showed AML post-MDS (No. 6) and secondary to MM (No. 2), respectively; and the last one (No. 17) was in second CR at the moment of transplantation.
Cytogenetic studies
Cytogenetic studies were performed at diagnosis on BM in all the patients. The patients with abnormal karyotype were studied before and after transplantation at different stages to evaluate the cytogenetic remission. The collections of PBSCs were cytogenetically studied in all patients. The karyotype was performed after a short-term culture (24 and/or 48 h) with no stimulation of BM cells and after 1-5 days with or without PHA leucocyte culture medium (PHA-LCM) on apheretic collection according to the standard technique. G-banding with Wright's stain was performed. Chromosomes were classified according to the International Standard Nomenclature. 12 The number of cytogenetic studies on BM was variable: two to 11 studies (median number, 8) were performed for each patient. A median number of 30 (range, 10-55) metaphases was observed for each study. In all the patients the apheretic collection was studied and a median number of 18.5 (range, 10-50) metaphases was observed.
FISH
Fixed cell suspensions stored at 4°C were used for FISH studies in two cases: one patient with 7 monosomy and another with 8 trisomy as the only abnormality.
A digoxigenin-labeled probe specific to the 8 ␣-satellite region (D8Z2; Oncor, Gaithersburg, MD, USA) and a Spectrum Green CEP7 ␣-satellite (Vysis, Downers Grove, IL, USA) were used to detect the abnormal cells. The cells were analysed in the fluorescence microscope with a double pass filter (PI-FITC). Per slide, 200-1000 nuclei were scored. For each probe of this study, control samples were performed. The cut-off for recognising trisomy 8 and monosomy 7 was set at 3% and 5% interphase cells showing three and one well-delineated signals, respectively, according to our control values.
Molecular studies
Molecular studies were performed in five patients carrying a chromosomal translocation, encoding to a specific chimeric mRNA, as well as: t(15;17)(q12;q21) in one patient; inv(16)(p13q22) in two patients; t(8;21)(q22;q22) in two patients with RT-PCR technologies. Total RNA from Ficoll-Hypaque-separated mononuclear cells from bone marrow aspirates and from leukapheresed cells were subjected to RT-PCR procedures for amplification of PML-RAR␣, CBF␤/MYH11 and AML1/ETO transcripts, respectively, as already described. [13] [14] [15] [16] [17] PCR amplification for PML-RAR␣ rearrangement was performed by the use of R8 primer: 5Ј-CAGAACTGCTGCTCTGGGT-CTCAAT-3Ј as the 3Ј primer and the sense primers: M2 5'-AGTGTACGCCTTCTCCATCA-3'; M4 5Ј-AGCTGC-TGGAGGCTGTGGTGCTTTGAGTG-3Ј; M5 5Ј-GAC-TTCTGGTGCTTTGAGTG-3Ј as the 5Ј primers. 13, 14 For the detection of CBFB/MYH11 the oligonucleotides and primers used were: 2M-M1 5Ј-CTCCTCTCCTCATTC-TGCTC-3Ј; M2 5Ј-ACTGCAGCTCCTGCACCTGC-3Ј; C1 5Ј-GCAGGCAAGGTATATTTGAAGG-3Ј; 1 5Ј-CAG-GCAAGGTATATTTGAAGG-3Ј; probe A 5Ј-TGGATG-GTATGGGCTGTCTG-3Ј; probe B 5Ј-CGCTCCTCAT-CAAACTCCAGA-3Ј. 15, 16 Finally, for AML1-ETO rearrangement, PCR was carried out using two separate sets of amplimers. An AML1-AML1 fragment of 158 bp was amplified as an internal control using the following primers: 5Ј-AGCTTCACTCTGACCATCAC-3Ј (primer A) and 5Ј-TGAACTGGTTCTTGGAGCTCCT-3Ј (primer B, also used in RT reaction). An AML1/ETO fusion fragment of 222 bp was amplified with: primer A and 5Ј-TGAACTGGTTCTTGGAGCTCCT-3Ј (reverse of a 3Ј ETO sequence; primer C also employed in the RT Table 3 Evaluation of leukaemic contamination by conventional cytogenetics (CC) (abnormal/total observed metaphases), FISH reaction). 17 Ten microlitres of the PCR mixture was electrophoresed on a 2.5-3% agarose gel, and visualised by staining with ethidium bromide.
Statistical analysis
Fisher's exact test was applied to analyse the differences between the patients with and without residual leukaemic cells, in terms of survival and CCR (continuous complete remission).
Results
Leukapheresis contamination
We detected leukaemic cells in PBSC harvests of four patients (Table 3) No. 14 demonstrated the same alterations as at diagnosis in two out of 10 observed BM cells in BM assessed early after the aphereses. Thus, the patient was not submitted to transplantation.
In patient No. 3, who was karyotypically normal, FISH studies detected 6.8% and 17.2% of PBSC and BM interphase cells, respectively, carrying monosomy 7 ( Figure 1) .
The last patient (No. 17) was PCR-positive for PML-RAR␣ both in PBSC harvest and BM before transplantation, while the cytogenetic studies showed normal karyotype in both samples.
Patient No. 14 was not reinfused and patients 3, 12 and 17 relapsed 4, 4 and 2 months, respectively, after PBSC transplantation. Only patient No. 12 is alive and well after reinduction therapy. 
Bone marrow contamination
The presence of leukaemic cells only in the BM before transplantation was observed in three patients (Table 3) . Whereas two of them were in early relapse (Nos 2 and 11), patient No. 4 was in clinical and cytogenetic remission: 5.6% of cells were detected by FISH, and she relapsed and died 4 months after transplantation. Patient No. 2 is alive with RAEB-T at 32 months from transplantation and patient No. 11 is alive and well with no sign of relapse at 19 months after autograft.
A significant (P = 0.04) reduction in overall survival was observed in patients with leukaemic contamination both in the PBSC harvest and BM before transplantation, as opposed to those showing no contamination in both samples. Relapse-free survival was correlated with the absence of contamination in either BM or PBSC harvest. These results have to be considered with caution because of the low number of patients involved in this study.
Discussion
Leukaemic relapse remains the most frequent cause of treatment failure in AML patients undergoing autologous PBSC transplantation. 18 It is therefore reasonable to assume that PBSC collections may contain leukaemic cells, and strategies to address this problem have to be developed. Recently, gene marking studies demonstrated that the presence of leukaemic cells in BM harvests contribute to disease relapse. 9 To our knowledge, there are few reports concerning neoplastic contamination in PBSC harvests from AML and MDS patients. [19] [20] [21] [22] Leukaemic cells can be detected by morphologic and cytochemical analysis. However, these assays are extremely insensitive. Better methods are based on the identification of karyotype abnormalities by conventional cytogenetics, in situ hybridisation and molecular techniques. A recent PCR-based study performed on six patients with Philadelphia (Ph)-positive acute leukaemia and acute promyelocytic leukaemia (APL) did not support the hypothesis that PBSC collections are less contaminated by leukaemic cells than BM harvests. Indeed, the authors suggested that PBSC are contaminated when BM is contaminated. 19 Here, we extend the analysis of tumour cell contamination in leukaphereses and BM to 18 AML and MDS patients. It should be noted that in 11 patients only cytogenetic studies were performed. Conversely, in seven patients the use of FISH and RT-PCR detecting the persistence of neoplastic cells could be applied with more sensitivity, demonstrating the presence of leukaemic cells in three patients (Nos 3, 4 and 17) who were in clinical and cytogenetic remission.
In our series, four out of 18 patients showed leukaemic contamination in apheretic collections. Only one patient (No. 12) demonstrated leukaemic cells in PBSC but not in BM cells before reinfusion, while three patients (Nos 3, 14 and 17) had leukaemic cells in both samples. Three (Nos 3, 12 and 14) out of these four patients underwent transplantation and relapsed 4, 4 and 2 months later, respectively (Table 2) .
In addition, three other patients showed contamination only in BM cells before transplantation and two patients (Nos 2 and 4) relapsed shortly after autograft. Five more patients in complete cytogenetic remission relapsed after transplantation. Three of these patients had secondary AML (s-AML) or therapy related-AML (t-AML). In particular, one patient, carrying inv(16), did not show contamination either of BM or PBSC detected by cytogenetic and molecular studies (Figure 2) . This study confirms that the presence of neoplastic cells in autologous grafts correlates with a poor prognosis, as already demonstrated in similar studies on autologous ABMT. 23, 24 Moreover, PBSC collections do not seem to be more contaminated than BM harvests and leukaemic cells are detectable in PBSC when the BM is not disease-free. Conversely, except patient No. 12, we did not find leukaemia in leukaphereses from patients, considered in CR by cytogenetics, FISH or RT-PCR. Nevertheless, some patients relapsed despite the absence of leukaemic cells in apheretic collections and in the BM analysed shortly before stem cell reinfusion. We conclude that the lack of detection of leukaemia cannot be said to be predictive of long-term disease-free survival, even when PCR-based methods are employed. In fact, the disease relapse may be due to tumour cells resistant, in vivo, to the conditioning regimen. However, more patients need to be tested with more sensitive techniques than cytogenetic studies.
More effective methods for in vivo and, if possible, ex vivo purging of leukaemic cells are required to decrease the incidence of disease recurrence.
